ClearPoint Neuro以5M美元的现金和库存获得IRRAS,并获得了脑出血装置和客户。 ClearPoint Neuro acquired IRRAS for $5M cash and stock, gaining its brain bleeding device and customers.

ClearPoint Neuro于2025年11月20日完成对IRRAS控股的收购,支付了500万美元现金,发行了13.25万股,并附加了收入分享条件。 ClearPoint Neuro completed its acquisition of IRRAS Holdings on November 20, 2025, paying $5 million in cash and issuing 1.325 million shares, with additional revenue-sharing terms. 这笔交易增加了IRRAAS的IRRAFLL系统,该系统与50多个客户和一个商业团队一起用于管理腹腔内出血。 The deal adds IRRAS’s IRRAflow system, used to manage intracranial bleeding, along with over 50 customers and a commercial team. 这一整合扩大了ClearPoint在神经关键护理方面的覆盖范围,加强了其中枢神经系统药物交付平台。 The integration expands ClearPoint’s reach in neurocritical care and strengthens its platform for central nervous system drug delivery. 从2025年第四季度开始,IRRAS的财务结果将列入ClearPoint的综合报表。 IRRAS’s financial results will be included in ClearPoint’s consolidated statements starting in the fourth quarter of 2025.